Why the study?
The role of assessing left ventricular adverse remodeling (LVAR) in predicting cardiovascular events remains controversial, and optimal definitions to add prognostic value to early CMR are needed.
Does the assessment of left ventricular adverse remodeling at 6 months add prognostic information to early CMR in patients with reperfused STEMI?
Does the assessment of left ventricular adverse remodeling at 6 months add prognostic information to early CMR in patients with reperfused STEMI?
Assessment of left ventricular adverse remodeling at 6 months does not improve prognostic information beyond what is provided by early cardiac magnetic resonance in patients with reperfused STEMI.
Answers are grounded in this paper and cite their sources.
Early CMR may suffice for prognostication in reperfused STEMI without routine 6-month LVAR; leaves open prospective validation of serial imaging.
OBJECTIVES: This study sought to establish the best definition of left ventricular adverse remodeling (LVAR) to predict outcomes and determine whether its assessment adds prognostic information to that obtained by early cardiac magnetic resonance (CMR). BACKGROUND: LVAR, usually defined as an increase in left ventricular end-diastolic volume (LVEDV) is the main cause of heart failure after an ST-segment elevated myocardial infarction; however, the role of assessment of LVAR in predicting cardiovascular events remains controversial. METHODS: Patients with ST-segment elevated myocardial infarction who received percutaneous coronary intervention within 6 h of symptom onset were included (n = 498). CMR was performed during hospitalization (6.2 ± 2.6 days) and after 6 months (6.1 ± 1.8 months). The optimal threshold values of the LVEDV increase and the LV ejection fraction decrease associated with the primary endpoint were ascertained. Primary outcome was a composite of cardiovascular mortality, hospitalization for heart failure, or ventricular arrhythmia. RESULTS: The study was completed by 374 patients. Forty-nine patients presented the primary endpoint during follow-up (72.9 ± 42.8 months). Values that maximized the ability to identify patients with and without outcomes were a relative rise in LVEDV of 15% (hazard ratio [HR]: 2.1; p = 0.007) and a relative fall in LV ejection fraction of 3% (HR: 2.5; p = 0.001). However, the predictive model (using C-statistic analysis) failed to demonstrate that direct observation of LVAR at 6 months adds information to data from early CMR in predicting outcomes (C-statistic: 0.723 vs. 0.795). CONCLUSIONS: The definition of LVAR that best predicts adverse cardiovascular events should consider both the increase in LVEDV and the reduction in LV ejection fraction. However, assessment of LVAR does not improve information provided by the early CMR.
No takes yet. Share an insight, caveat, or question.
Rodríguez‐Palomares et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: